...
首页> 外文期刊>Digestive endoscopy: official journal of the Japan Gastroenterological Endoscopy Society >Endoscopic ultrasound‐guided versus endoscopic retrograde cholangiopancreatography‐guided biliary drainage for primary treatment of distal malignant biliary obstruction: A systematic review and meta‐analysis
【24h】

Endoscopic ultrasound‐guided versus endoscopic retrograde cholangiopancreatography‐guided biliary drainage for primary treatment of distal malignant biliary obstruction: A systematic review and meta‐analysis

机译:内窥镜超声引导与内窥镜逆行胆管胆管造影引导的胆道引流用于远端恶性胆道阻塞的主要治疗:系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives Current evidence supporting the utility of endoscopic ultrasound‐guided biliary drainage ( EUS ‐ BD ) as primary treatment for distal malignant biliary obstruction ( MBO ) is limited. We conducted a meta‐analysis to compare the performance of EUS ‐ BD and endoscopic retrograde cholangiopancreatography‐guided biliary drainage ( ERCP ‐ BD ) as primary palliation of distal MBO . Methods We searched several databases for comparative studies evaluating EUS ‐ BD vs. ERCP ‐ BD in primary drainage of distal MBO up to 28 February 2019. Primary outcomes were technical success and clinical success. Secondary outcomes included adverse events, stent patency, stent dysfunction, tumor in/overgrowth, reinterventions, procedure duration, and overall survival. Results Four studies involving 302 patients were qualified for the final analysis. There was no difference in technical success (risk ratio [ RR ] 1.00; 95% confidence interval [95% CI ] 0.93–1.08), clinical success ( RR 1.00; 95% CI 0.94–1.06) and total adverse events ( RR 0.68; 95% CI : 0.31–1.48) between the two procedures. EUS ‐ BD was associated with lower rates of post‐procedure pancreatitis ( RR 0.12; 95% CI 0.02–0.62), stent dysfunction ( RR 0.54; 95% CI 0.32–0.91), and tumor in/overgrowth ( RR 0.22; 95% CI 0.07–0.76). No differences were noted in reinterventions ( RR 0.59; 95% CI 0.21–1.69), procedure duration (weighted mean difference ?2.11; 95% CI ?9.51 to 5.29), stent patency (hazard ratio [ HR ] 0.61; 95% CI 0.34–1.11), and overall survival ( HR 1.00; 95% CI 0.66–1.51). Conclusions With adequate endoscopy expertise, EUS ‐ BD could show similar efficacy and safety when compared with ERCP ‐ BD for primary palliation of distal MBO and exhibits several clinical advantages.
机译:目的目前支持内窥镜超声引导胆道引流(EUS - BD)作为远端恶性胆道阻塞(MBO)的主要治疗的效用。我们进行了一个荟萃分析,以比较EUS - BD和内窥镜逆行胆管痴呆症导向胆道引导(ERCP - BD)作为远端MBO的初级粘液的性能。方法我们在2019年2月28日期,我们在初级排水中搜索了评估EUS - BD与ERCP - BD的比较研究的几个数据库。主要结果是技术成功和临床成功。二次结果包括不良事件,支架通畅,支架功能障碍,肿瘤/过度生长,重新融合,程序持续时间和整体存活。结果涉及302名患者的四项研究有资格获得最终分析。技术成功没有差异(风险比[RR] 1.00; 95%置信区间[95%CI] 0.93-1.08),临床成功(RR 1.00; 95%CI 0.94-1.06)和总不良事件(RR 0.68;两种程序之间的95%CI:0.31-1.48)。 EUS - BD与术后胰腺炎的较低率(RR 0.12; 95%CI 0.0.62),支架功能障碍(RR 0.54; 95%CI 0.32-0.91),以及肿瘤/过度生长(RR 0.22; 95%) CI 0.07-0.76)。在重新纳费中没有注意到差异(RR 0.59; 95%CI 0.21-1.69),程序持续时间(加权平均差异?2.11; 95%CI?9.51至5.29),支架通畅(危险比[HR] 0.61; 95%CI 0.34 -1.11)和整体存活(HR 1.00; 95%CI 0.66-1.51)。结论与充足的内窥镜专业知识,EUS - BD与ERCP - BD相比,对于远端MBO的初级粘连,表现出几种临床优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号